WO2011010967A1 - Process for producing flurocytidine derivatives - Google Patents
Process for producing flurocytidine derivatives Download PDFInfo
- Publication number
- WO2011010967A1 WO2011010967A1 PCT/SG2010/000276 SG2010000276W WO2011010967A1 WO 2011010967 A1 WO2011010967 A1 WO 2011010967A1 SG 2010000276 W SG2010000276 W SG 2010000276W WO 2011010967 A1 WO2011010967 A1 WO 2011010967A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- impurity
- formula
- compound
- capecitabine
- area percent
- Prior art date
Links
- FLPQJCQCNIDCJR-WYHSEJQZSA-N CCCCCOC(NC(C(F)=CN1C([C@@H]2OC(C)=O)OC(C)[C@H]2O)=NC1=O)=O Chemical compound CCCCCOC(NC(C(F)=CN1C([C@@H]2OC(C)=O)OC(C)[C@H]2O)=NC1=O)=O FLPQJCQCNIDCJR-WYHSEJQZSA-N 0.000 description 1
- KXADSCDBIKQHCV-USEQNBQGSA-N CCCCCOC(NC(C(F)=CN1[C@@](COC2C)([C@@H]2OC(C)=O)O)=NC1=O)=O Chemical compound CCCCCOC(NC(C(F)=CN1[C@@](COC2C)([C@@H]2OC(C)=O)O)=NC1=O)=O KXADSCDBIKQHCV-USEQNBQGSA-N 0.000 description 1
- 0 C[C@@]([C@@]([C@]1O)O)OC1N(C=C(C(NC(O*)=O)=N1)F)C1=O Chemical compound C[C@@]([C@@]([C@]1O)O)OC1N(C=C(C(NC(O*)=O)=N1)F)C1=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present application relates to a process for manufacture of 5'- deoxy-5-fluoro-N 4 -n-pentyloxycarbonylcytidine (capecitabine) and its derivatives.
- Capecitabine is a fluoropyrimidine carbamate with antineoplastic activity and is commercially available in the market under the brand name XELODA ® , having the following chemical structure:
- capecitabine is described in several publications including U.S. Patent Nos. 5,472,949; 4,966,891 ; 5,453,497; 7,365,188; and
- One aspect of the present application provides a process of making a purified compound of formula (I):
- R 3 is alkyl, cycloalkyl, aralkyl, aryl, or alkoxy, preferably C1-C12 alkyl, cycloalkyl, aralkyl, aryl, or alkoxy, and more preferably C1-C6 alkyl.
- the hydroxyl protecting group is acetyl or benzoyl.
- X in the above acylating agent of formula (III) is preferably halide, more preferably chloride.
- the acylating agent of formula (III) is preferably n- pentyl chloroformate.
- the compound of formula (I) is preferably capecitabine, i.e., R 3 in the above formula (I) is a pentyl group.
- the reacting step (a) in the above process is preferably carried out in the presence of a base.
- the base is preferably in an amount from 3.5 to 5.0, more particularly about 4.0 mole equivalents of the compound of formula (II).
- the base is preferably pyridine.
- the deprotecting step(b) in the above process is preferably carried out in the presence of a base.
- the base is preferably sodium hydroxide.
- the deprotecting step (b) is accomplished by a hydrolysis reaction in a temperature of from about 0 to 10 0 C, more particularly from about 0 to 5 0 C.
- the reacting step (a) and deprotecting step (b) are successively carried out in the same reactor.
- the process of the present application may be carried out in one pot.
- the process as described above does not comprise a step of silylating the compound of formula (II) or any compound coupled by a 5- fluorocytosine or its derivative with a 5-deoxy furanoside or its derivative.
- the purifying step c) of the above process is preferably carried out at a temperature of less than 60 0 C.
- the solvent used in the purifying step may be water, ketone, ester (such as ethyl acetate), alcohol, ether, and combinations thereof.
- the solvent may be water, n-pentanol, a mixture of n-pentanol and n-heptane, and a mixture of ethyl acetate and n- heptane.
- the purifying step comprises crystallizing the compound of formula (I) from n-pentanol alone or a mixture of n-pentanol with one or more other solvents.
- capecitabine having the following mean particle size distribution:
- D 90 250 to 350 microns
- D 50 100 to 120 microns
- Di 0 25 to 30 microns.
- Yet another aspect of the present application provides a process of making capecitabine.
- the process comprises deprotecting a compound of formula (IV)
- Ri and R 2 independently represents a hydroxyl protecting group
- R 3 is alkyl, cycloalkyl, aralkyl, aryl, or alkoxy, preferably C- ⁇ C- ⁇ 2 alkyl, cycloalkyl, aralkyl, aryl, or alkoxy, more preferably, Ci ⁇ C6 alkyl.
- Ri and R 2 both represent the same hydroxyl protecting group, such as acetyl and benzoyl.
- the enzyme is lipase.
- the reaction temperature is preferably from 20 to 6O 0 C.
- the reaction pH range is preferably from 4 to 9.
- R 3 is preferably a pentyl group.
- the enzyme may deprotect the 2' and 3' position protecting groups with high specificity.
- enzymatic hydrolysis may be carried out in mild condition, and the enzyme may be used repeatedly.
- capecitabine comprising:
- impurity F no more than 0.2% by HPLC area percent (A%) of impurity G,
- the present application provides an improved process for industrial scale and a facile final purification of the compound of formula (I), in particular capecitabine, with high purity (>99.5%) and less undesired alpha-form impurity.
- capecitabine purified under water system.
- the purity of capecitabine is >99.4% (by HPLC area percent (A%)), impurity F ⁇ 0.3%, impurity G ⁇ 0.2%, impurity H ⁇ 0.3%, M2 ⁇ 0.1%, impurity M ⁇ 0.10% and the maximum individual impurity is ⁇
- the crude capecitabine may be purified under ethyl acetate system.
- the purity of capecitabine is >99.5%, impurity F ⁇ 0.3%, impurity G ⁇ 0.2%, impurity H ⁇ 0.3%, M2 ⁇ 0.1%, impurity M ⁇ 0.10% and the maximum individual impurity is ⁇ 0.1%.
- the inventors of this invention have developed a novel process for deprotection of protecting groups of capecitabine selectively with enzyme.
- Enzymatic hydrolysis can be carried out in mild condition and the enzyme may be used repeatedly.
- enzymatic hydrolysis reaction can avoid the side products and other impurities produced during the deprotection step.
- the enzymatic hydrolysis reaction comprises treating a compound of formula (IV) with enzyme to selectively deacylate the 2' and 3' positions of the carbohydrate moiety to produce capecitabine.
- each of Ri and R 2 is independently a hydroxyl protecting group.
- Example 1 A process for producing and purification of 2',3'-di-O-acetyl-5'- deoxy-5-fluorocytidine (I)
- the solution is cooled to 20-30 0 C and worked up with saturated sodium bicarbonate solution. After phase separation with methylene chloride, the organic layer is collected and subsequently swapped with isopropanol (7.76 kg) to an appropriate volume. The resulting
- isopropanol solution is heated to reflux until dissolved.
- the solution is cloud after seeding with 2',3'-di-O-acetyl-5'-deoxy-5-fluorocytidine at 50-70 0 C.
- the slurry is cooled to room temperature and n-heptane is charged with stirring for another 0.5 hrs.
- the solution is cooled to less than 10 0 C.
- the resulting solid is filtered, washed with cold isopropanol and dried under vacuum, to afford 2',3'-di-O-acetyl-5'-deoxy-5-fluorocytidine.
- the purity is >99.5% and related alpha-form impurity is ⁇ 0.2%. Yield: 80%.
- Example 2 A process for producing and purification of 2',3'-di-O-acetyl-5- deoxy-5-fluoro-N4-(pentyl-oxycarbonyl)cytidine (II) [0031] To a vessel is added of 2 ⁇ 3'-di-O-acetyl-5'-deoxy-5-fluorocytidine (0.2 kg, 0.6 mol), methylene chloride (1.59 Kg) and pyridine (190.Og, 2.4 mol) at 20-30 0 C. The mixture is cooled to below 5°C and subsequently is added of n-pentylchloroformate (137.2 g, 0.9 mol) at below 10 0 C.
- the resulting solution is stirred at less than 10 0 C for at least 0.5 hour.
- water (2 Kg) is added for phase separation.
- the organic layer is collected and washed with water (2 kg) for three times.
- organic layer is collected and swapped with toluene (0.4 Kg) under vacuum at less than 60 0 C.
- n-heptane (0.3 kg) is added to cloud point at 40- 50 0 C.
- n-heptane (0.4 kg) is added and the slurry is cooled to less than 10 0 C.
- the solution keeps stirring for at least 1 hour.
- Example 3 A process for producing and purification of capecitabine under water system
- the organic layer is collected and the aqueous is continued to wash with methylene chloride (40 ml_). After phase separation, the methylene chloride layer is collected and combined with the previous organic layer. The resulting organic layer is washed with water (100 g) and the organic layer is collected. The organic layer is concentrated and then is swapped with water (100 g) under vacuum at less than 60 0 C. After solvent swap, the resulting solution is heated at 40-55 0 C and seeded with capecitabine. The mixture is held for about 1 hour at 20-55 0 C and cooled to -5 to 5°C. The slurry is stirred at -5 to 5°C for about 2 hours.
- the resulting solid is filtered, washed with cold water and dried under vacuum to afford capecitabine.
- the purity is >99.4%, impurity F ⁇ 0.3%, impurity G ⁇ 0.2%, impurity H ⁇ 0.3%, M2 ⁇ 0.1%, impurity M ⁇ 0.10% and the maximum individual impurity is ⁇ 0.1 %. Yield: 47%.
- Example 4 A process for producing and purification of capecitabine under ethyl acetate system
- the organic layer is collected and the aqueous is continued to wash with methylene chloride (40 ml_). After phase separation, the methylene chloride layer is collected and combined with the previous organic layer. The resulting organic layer is washed with water (100 g) and the organic layer is collected. The organic layer is concentrated and then is swap with ethyl acetate (60 ml_) under vacuum at less than 60 0 C. After solvent swap, n- heptane (20 ml_) is added and the resulting solution is heated at 40-55°C and seeded with capecitabine. The mixture is held for about 1 hour at 40- 55°C and cooled to -5 to 5°C.
- the slurry is stirred at -5 to 5°C for about 2 hours.
- the resulting solid is filtered, washed with n-heptane and dried under vacuum to afford capecitabine.
- the purity is >99.5%, impurity F ⁇ 0.3%, impurity G ⁇ 0.2%, impurity H ⁇ 0.3%, M2 ⁇ 0.1%, impurity M ⁇ 0.10% and the maximum individual impurity is ⁇ 0.1%. Yield: 85%.
- Example 5 A process for producing and purification of capecitabine from 2',3'-di-O-acetyl-5'-deoxy-5-fluorocytidine in One-Pot reaction
- n-pentylchloroformate 22 kg, 146.1 mol
- the resulting solution is stirred at less than 10 0 C for at least 0.5 hour.
- water (500 g) is added for phase separation.
- the organic layer is collected and washed with water (500 g) for about three times.
- organic layer is collected and transferred to a vessel.
- methanol (38.7 g) is added at below 5°C.
- 25% NaOH 36 g, 0.22 mol
- the resulting solution is maintained at below 5°C and stirred for at least 0.5 hour.
- citric acid (135 g) is added for quenching the reaction and doing phase separation.
- the organic layer is collected and the aqueous is continued to wash with methylene chloride (112 g). After phase separation, the methylene chloride layer is collected and combined with the previous organic layer.
- the resulting organic layer is washed with water (225 g) and the organic layer is collected.
- the organic layer is concentrated and then is swapped with n- pentanol (225 ml_) under vacuum at less than 6O 0 C. After solvent swap, the resulting solution is heated at 40-55 0 C and seeded with capecitabine. The mixture is held for about 1 hour at 40-55 0 C and cooled down to -5 to 5°C. The slurry is stirred at -5 to 5°C for about 2 hours.
- the resulting solid is filtered, washed with n-heptane and dried under vacuum to afford
- the purity is >99.5%, impurity F ⁇ 0.3%, impurity G ⁇ 0.2%, impurity H ⁇ 0.3%, M2 ⁇ 0.1 %, impurity M ⁇ 0.10% and the maximum individual impurity is ⁇ 0.1%. Yield: 77%.
- Example 6 A process for producing and purification of capecitabine under n- pentanol and a mixed solvent system
- n-heptane (0.68 kg) is added and the resulting solution is heated at 40-60 0 C and seeded with capecitabine. The mixture is held for about 1 hour at 40-60 0 C and cooled down to -5 to 5°C. The slurry is stirred at -5 to 5°C for about 2 hours. The resulting solid is filtered, washed with n-heptane and dried under vacuum to afford
- capecitabine (0.9 kg), Yield: about 80%.
- the purity is > 99.5%, impurity F ⁇ 0.3%, impurity G ⁇ 0.2%, impurity H ⁇ 0.3%, M2 ⁇ 0.1 %, impurity M ⁇ 0.10% and the maximum individual impurity is ⁇ 0.1%.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012521599A JP2012533618A (en) | 2009-07-23 | 2010-07-21 | Process for producing fluorocytidine derivatives |
EP10802524.8A EP2456778A4 (en) | 2009-07-23 | 2010-07-21 | Process for producing flurocytidine derivatives |
CN2010800325446A CN102858791A (en) | 2009-07-23 | 2010-07-21 | Process for producing flurocytidine derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22797109P | 2009-07-23 | 2009-07-23 | |
US61/227,971 | 2009-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011010967A1 true WO2011010967A1 (en) | 2011-01-27 |
Family
ID=43497887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SG2010/000276 WO2011010967A1 (en) | 2009-07-23 | 2010-07-21 | Process for producing flurocytidine derivatives |
Country Status (8)
Country | Link |
---|---|
US (1) | US20110021769A1 (en) |
EP (1) | EP2456778A4 (en) |
JP (1) | JP2012533618A (en) |
KR (1) | KR20120037932A (en) |
CN (1) | CN102858791A (en) |
AR (1) | AR077498A1 (en) |
TW (1) | TW201103550A (en) |
WO (1) | WO2011010967A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103059085A (en) * | 2011-12-27 | 2013-04-24 | 石药集团中奇制药技术(石家庄)有限公司 | Anti-cancer medicament intermediate and preparation method thereof |
CN103183713A (en) * | 2011-12-31 | 2013-07-03 | 沈阳药科大学 | Preparation method of 5-deoxy-D-ribofuranose oxygen glycosides compound |
CN104628804A (en) * | 2015-01-30 | 2015-05-20 | 吉林修正药业新药开发有限公司 | Synthesis method of capecitabine impurity acetyl condensate |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103910773B (en) * | 2014-04-08 | 2015-11-25 | 宁波美诺华药业股份有限公司 | The synthetic method of capecitabine impurity |
CN106496294B (en) * | 2016-09-21 | 2018-10-30 | 齐鲁天和惠世制药有限公司 | A method of preparing micro powder type capecitabine |
CN107936075A (en) * | 2017-12-28 | 2018-04-20 | 山东铂源药业有限公司 | A kind of synthetic method of capecitabine intermediate |
CN109651466A (en) * | 2018-12-20 | 2019-04-19 | 深圳市祥根生物科技有限公司 | The preparation method of capecitabine impurity G |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0602454B1 (en) * | 1992-12-18 | 1996-04-24 | F. Hoffmann-La Roche Ag | N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines |
CN1935828A (en) * | 2006-10-31 | 2007-03-28 | 浙江海正药业股份有限公司 | Fluoropyrimidine compound carbalkoxylation method |
WO2008131062A2 (en) * | 2007-04-20 | 2008-10-30 | Dr. Reddy's Laboratories Ltd. | Process for preparing capecitabine |
WO2008145403A1 (en) * | 2007-06-01 | 2008-12-04 | Synthon B.V. | Processes related to making capecitabine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1327358C (en) * | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
TW254946B (en) * | 1992-12-18 | 1995-08-21 | Hoffmann La Roche | |
KR101013312B1 (en) * | 2007-11-19 | 2011-02-09 | 한미홀딩스 주식회사 | Method for the preparation of capecitabine and method for the preparation of ?-anomer enriched trialkylcarbonate compound used therein |
-
2010
- 2010-07-21 EP EP10802524.8A patent/EP2456778A4/en not_active Withdrawn
- 2010-07-21 KR KR1020127000421A patent/KR20120037932A/en not_active Application Discontinuation
- 2010-07-21 JP JP2012521599A patent/JP2012533618A/en not_active Abandoned
- 2010-07-21 CN CN2010800325446A patent/CN102858791A/en active Pending
- 2010-07-21 WO PCT/SG2010/000276 patent/WO2011010967A1/en active Application Filing
- 2010-07-21 US US12/840,490 patent/US20110021769A1/en not_active Abandoned
- 2010-07-23 AR ARP100102691A patent/AR077498A1/en unknown
- 2010-07-23 TW TW099124113A patent/TW201103550A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0602454B1 (en) * | 1992-12-18 | 1996-04-24 | F. Hoffmann-La Roche Ag | N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines |
CN1935828A (en) * | 2006-10-31 | 2007-03-28 | 浙江海正药业股份有限公司 | Fluoropyrimidine compound carbalkoxylation method |
WO2008131062A2 (en) * | 2007-04-20 | 2008-10-30 | Dr. Reddy's Laboratories Ltd. | Process for preparing capecitabine |
WO2008145403A1 (en) * | 2007-06-01 | 2008-12-04 | Synthon B.V. | Processes related to making capecitabine |
Non-Patent Citations (1)
Title |
---|
See also references of EP2456778A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103059085A (en) * | 2011-12-27 | 2013-04-24 | 石药集团中奇制药技术(石家庄)有限公司 | Anti-cancer medicament intermediate and preparation method thereof |
CN103059085B (en) * | 2011-12-27 | 2015-09-02 | 石药集团中奇制药技术(石家庄)有限公司 | A kind of Anti-cancer medicament intermediate and preparation method thereof |
CN103183713A (en) * | 2011-12-31 | 2013-07-03 | 沈阳药科大学 | Preparation method of 5-deoxy-D-ribofuranose oxygen glycosides compound |
CN103183713B (en) * | 2011-12-31 | 2015-08-05 | 沈阳药科大学 | The preparation method of 5-deoxy-D-ribofuranose oxygen glycosides compound |
CN104628804A (en) * | 2015-01-30 | 2015-05-20 | 吉林修正药业新药开发有限公司 | Synthesis method of capecitabine impurity acetyl condensate |
Also Published As
Publication number | Publication date |
---|---|
AR077498A1 (en) | 2011-08-31 |
US20110021769A1 (en) | 2011-01-27 |
JP2012533618A (en) | 2012-12-27 |
EP2456778A1 (en) | 2012-05-30 |
CN102858791A (en) | 2013-01-02 |
TW201103550A (en) | 2011-02-01 |
KR20120037932A (en) | 2012-04-20 |
EP2456778A4 (en) | 2013-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2456778A1 (en) | Process for producing flurocytidine derivatives | |
WO2010017547A1 (en) | Process for making 5-azacytosine nucleosides and their derivatives | |
CN101657462A (en) | The Preparation Method And Their Intermediate of capecitabine | |
US8193354B2 (en) | Process for preparation of Gemcitabine hydrochloride | |
CA2704815C (en) | Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein | |
EP0653436A1 (en) | 5-Methyluridine process for large-scale preparation of 2',3'-didehydro-3'-deoxythymidine (d4T) | |
WO2008129530A1 (en) | Gemcitabine production process | |
US20090221811A1 (en) | Process for preparing gemcitabine and associated intermediates | |
KR20080079833A (en) | Methods for the stereoselective preparation and separation of tri-o-acetyl-5-deoxy-beta;-d-ribofuranose | |
AU2006325622B2 (en) | A manufacturing process of 2',2'-difluoronucleoside and intermediate | |
AU2006255706B2 (en) | Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside | |
WO2007070804A2 (en) | Process for preparing gemcitabine and associated intermediates | |
EP0495225A1 (en) | Process for the preparation of 3'fluoropyrimidine nucleosides | |
EP0523080A1 (en) | 3'-o-tosylcytidine and cytosine compounds, and process for production thereof. | |
JP5192807B2 (en) | Stable crystals of protected pseudouridine | |
KR20060102602A (en) | Novel process for preparation of clitocine | |
JP2007137843A (en) | Method for producing ribofuranose compound and purine nucleoside compound | |
KR20140007443A (en) | Synthesis of flg | |
WO2009082844A1 (en) | A capecitabine hydroxyl-derivative, its preparation processes and uses for preparing capecitabine | |
WO2010029574A2 (en) | An improved process for the preparation of gemcitabine and its intermediates using novel protecting groups and ion exchange resins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080032544.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10802524 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 20127000421 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 221/DELNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010802524 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012521599 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |